Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies

BACKGROUND: Lung cancer is now the leading cause of cancer mortality worldwide for both men and women. In non-small cell lung cancer (NSCLC), matching a specifically targeted drug to the identified driver mutation in each patient resulted in dramatically improved therapeutic efficacy, often in conju...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jiebai, Ding, Ning, Xu, Xiaobo, Zhang, Yong, Ye, Maosong, Li, Chun, Hu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325548/
https://www.ncbi.nlm.nih.gov/pubmed/32647540
http://dx.doi.org/10.1177/1758835920936090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325548/
https://www.ncbi.nlm.nih.gov/pubmed/32647540
http://dx.doi.org/10.1177/1758835920936090

Ejemplares similares